M P Pelletier1, S Solymoss, A Lee, R C Chiu. 1. Division of Cardiothoracic Surgery, The Montreal General Hospital, McGill University, Quebec, Canada.
Abstract
BACKGROUND: Reexploration of the mediastinum for bleeding is required in 3% to 7% of patients after cardiac operation, with many proving to have no surgically correctable cause. In spite of a "negative exploration," the bleeding often ceases. We propose the hypothesis that such a negative exploration can be therapeutic by reducing marked fibrinolytic activity in the mediastinal cavity. METHODS: Fibrinolytic activity in shed mediastinal blood was compared with that in the system blood in 5 patients after cardiac operation by measuring fibrinogen, fibrin degradation product, plasminogen activator inhibitor-1, and alpha2-antiplasmin levels. RESULTS: Fibrinolytic activity in mediastinal blood was markedly increased when compared with paired systemic venous blood. This was indicated by the mediastinal blood's lower fibrinogen levels (0.47 versus 1.91 U/mL; p < 0.001), very high levels of fibrin degradation products (1,350 versus 200 ng/mL; p < 0.05), and higher levels of plasminogen activator inhibitor-1 (55.5 versus 28.1 ng/mL; p < 0.005). Decreased levels of alpha2-antiplasmin were also observed in the mediastinum (0.50 versus 0.61 U/mL; p < 0.05). CONCLUSIONS: Our data confirm that fibrinolytic activity can be extremely high in the mediastinum in response to clot formation. This may explain the hemostatic effects of a negative reexploration, where irrigation and the removal of clots may reduce the fibrinolytic process; this may allow the bleeding ends of capillaries and small vessels to thrombose. Decreased levels of alpha2-antiplasmin observed suggest that lysine analogs, such as epsilon-aminocaproic acid, may have a beneficial role when locally delivered into the mediastinum.
BACKGROUND: Reexploration of the mediastinum for bleeding is required in 3% to 7% of patients after cardiac operation, with many proving to have no surgically correctable cause. In spite of a "negative exploration," the bleeding often ceases. We propose the hypothesis that such a negative exploration can be therapeutic by reducing marked fibrinolytic activity in the mediastinal cavity. METHODS: Fibrinolytic activity in shed mediastinal blood was compared with that in the system blood in 5 patients after cardiac operation by measuring fibrinogen, fibrin degradation product, plasminogen activator inhibitor-1, and alpha2-antiplasmin levels. RESULTS: Fibrinolytic activity in mediastinal blood was markedly increased when compared with paired systemic venous blood. This was indicated by the mediastinal blood's lower fibrinogen levels (0.47 versus 1.91 U/mL; p < 0.001), very high levels of fibrin degradation products (1,350 versus 200 ng/mL; p < 0.05), and higher levels of plasminogen activator inhibitor-1 (55.5 versus 28.1 ng/mL; p < 0.005). Decreased levels of alpha2-antiplasmin were also observed in the mediastinum (0.50 versus 0.61 U/mL; p < 0.05). CONCLUSIONS: Our data confirm that fibrinolytic activity can be extremely high in the mediastinum in response to clot formation. This may explain the hemostatic effects of a negative reexploration, where irrigation and the removal of clots may reduce the fibrinolytic process; this may allow the bleeding ends of capillaries and small vessels to thrombose. Decreased levels of alpha2-antiplasmin observed suggest that lysine analogs, such as epsilon-aminocaproic acid, may have a beneficial role when locally delivered into the mediastinum.
Authors: Eva Diephuis; Corianne de Borgie; Anton Tomšič; Jacobus Winkelman; Wim Jan van Boven; Berto Bouma; Susanne Eberl; Nicole Juffermans; Marcus Schultz; Jose P Henriques; David Koolbergen Journal: EBioMedicine Date: 2020-04-25 Impact factor: 8.143
Authors: Yvon Baribeau; Benjamin Westbrook; Yanick Baribeau; Simon Maltais; Edward M Boyle; Louis P Perrault Journal: J Cardiothorac Surg Date: 2019-11-08 Impact factor: 1.637
Authors: Eva C Diephuis; Corianne A de Borgie; A Zwinderman; Jacobus A Winkelman; Wim-Jan P van Boven; José P S Henriques; Susanne Eberl; Nicole P Juffermans; Marcus J Schultz; Robert J M Klautz; David R Koolbergen Journal: EClinicalMedicine Date: 2020-12-23
Authors: Johan S J Manshanden; Chantal L I Gielen; Corianne A J M de Borgie; Robert J M Klautz; Bas A J M de Mol; David R Koolbergen Journal: EBioMedicine Date: 2015-07-31 Impact factor: 8.143